The Hippo in the room: Targeting the Hippo signalling pathway for osteosarcoma therapies
- 22 July 2020
- journal article
- review article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (3) , 1606-1615
Abstract
Osteosarcoma (OS) is a primary malignant bone tumour which usually occurs in children and adolescents. OS is primarily a result of chromosomal aberrations, a combination of acquired genetic changes and, hereditary, resulting in the dysregulation of cellular functions. The Hippo signalling pathway regulates cell and tissue growth by modulating cell proliferation, differentiation, and migration in developing organs. Mammalian STE20‐like 1/2 (MST1/2) protein kinases are activated by neurofibromatosis type 2, Ras association domain family member 2, kidney and brain protein, or other factors. Interactions between MST1/2 and salvador family WW domain‐containing protein 1 activate large tumour suppressor kinase 1/2 proteins, which in turn phosphorylate the downstream Yes‐associated protein 1/transcriptional coactivator with PDZ‐binding motif (YAP/TAZ). Moreover, dysregulation of this pathway can lead to aberrant cell growth, resulting in tumorigenesis. Interestingly, small molecules targeting the Hippo signalling pathways, through affecting YAP/TAZ cellular localisation and their interaction with members of the TEA/ATTS domain family of transcriptional enhancers are being developed and hold promise for the treatment of OS. This review discusses the existing knowledge about the involvement of the Hippo signalling cascade in OS and highlights several small molecule inhibitors as potential novel therapeutics.Keywords
Funding Information
- Australian National Health and Medical Research Council (APP1107828, APP1127156, APP1163933)
This publication has 61 references indexed in Scilit:
- Ajuba Family Proteins Link JNK to Hippo SignalingScience Signaling, 2013
- Transcriptional Regulatory Cascades in Runx2-Dependent Bone DevelopmentTissue Engineering Part B: Reviews, 2013
- Mammalian Hippo signalling: a kinase network regulated by protein–protein interactionsBiochemical Society Transactions, 2012
- ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic proteinCancer Chemotherapy and Pharmacology, 2011
- WW domain interactions regulate the Hippo tumor suppressor pathwayCell Death & Disease, 2011
- A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcriptionThe Journal of Biochemistry, 2011
- The Hippo Signaling Pathway in Development and CancerDevelopmental Cell, 2010
- Functional and biological analysis of Bcl-xL expression in human osteosarcomaBone, 2010
- PDZ domains and their binding partners: structure, specificity, and modificationCell Communication and Signaling, 2010
- p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodelingJournal of Cell Biology, 2005